SPAIN, July 1, 2026
Telum Therapeutics announced the successful completion of an €18 million Series A financing round to accelerate the clinical development of its lead antimicrobial candidate for hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by multidrug-resistant Acinetobacter baumannii. The financing was led by the AMR Action Fund, with participation from Inveready and continued backing from Invivo Partners, CDTI through SICC Innvierte, Clave Capital, and Sodena. The investment will fund the advancement of Telum’s lead program through Phase 1 clinical trials, generating key safety and translational data while supporting expansion of the company’s broader antimicrobial pipeline. The funding marks a major milestone for the Spanish biotechnology company as it seeks to address the growing global threat of antimicrobial resistance (AMR) through next-generation, protein-based antimicrobial therapies.
Series A Financing Accelerates Lead Antimicrobial Candidate
The newly secured capital will primarily support the development of Telum’s lead therapeutic candidate targeting Acinetobacter baumannii, one of the most difficult multidrug-resistant bacterial pathogens responsible for severe hospital-acquired infections worldwide. Built using the company’s proprietary APEX® discovery platform, the investigational therapy is designed as a biologically derived protein-based antimicrobial capable of overcoming limitations associated with conventional antibiotics. Company executives stated that the financing provides a clear pathway to complete Phase 1 clinical development, while also strengthening translational research and manufacturing activities required for future clinical studies. The investment also allows Telum to continue expanding its pipeline targeting both Gram-negative and Gram-positive drug-resistant pathogens.
AMR Action Fund Backs Innovative Antibiotic Development
The AMR Action Fund, the world’s largest venture capital fund dedicated exclusively to antimicrobial therapeutics and diagnostics, led the financing round and will provide both capital and strategic expertise in antimicrobial resistance. Fund CEO Dr. Henry Skinner described Acinetobacter baumannii as one of modern medicine’s most dangerous bacterial threats due to its widespread resistance to first-line antibiotics and the limited number of available treatment options. Investors believe Telum’s innovative scientific approach offers the potential to develop an entirely new class of antimicrobial therapies capable of addressing life-threatening infections where existing antibiotics have become ineffective. According to Telum’s leadership, the participation of globally recognized AMR-focused investors validates both the strength of the company’s scientific platform and the growing need for innovative antimicrobial solutions.
Advertisement
Funding Strengthens Pipeline and Global Growth Strategy
Beyond advancing its lead pneumonia program, the Series A financing strengthens Telum Therapeutics’ long-term strategy of building a diversified portfolio of antimicrobial candidates using its proprietary APEX® platform, which integrates metagenomics, synthetic biology, and generative AI for drug discovery. Company executives said the funding reinforces Telum’s position within the international antimicrobial innovation ecosystem while providing the resources needed to accelerate research across multiple difficult-to-treat bacterial infections. The financing also highlights the growing role of Spain’s biotechnology sector and Navarra’s innovation ecosystem in supporting globally competitive life science companies developing therapies for urgent public health challenges. With antimicrobial resistance continuing to threaten healthcare systems worldwide, Telum aims to deliver novel treatment options capable of addressing critical unmet medical needs.
Source: Telum Therapeutics, press release
